



## Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes<sup>☆</sup>

Mitchell B. Rosen<sup>a,\*</sup>, Kaberi P. Das<sup>b</sup>, Carmen R. Wood<sup>b</sup>, Cynthia J. Wolf<sup>b</sup>,  
Barbara D. Abbott<sup>b</sup>, Christopher Lau<sup>b</sup>

<sup>a</sup> U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Integrated Systems Toxicology Division, Research Triangle Park, NC, USA

<sup>b</sup> U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Toxicology Assessment Division, Research Triangle Park, NC, USA

### ARTICLE INFO

#### Article history:

Received 13 February 2013

Received in revised form 22 March 2013

Accepted 25 March 2013

Available online 6 April 2013

#### Keywords:

Perfluorinated

Primary hepatocyte

Mouse

Human

Gene expression

Biological activity

### ABSTRACT

While perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) have been studied at length, less is known about the biological activity of other perfluoroalkyl acids (PFAAs) detected in the environment. Using a transient transfection assay developed in COS-1 cells, our group has previously evaluated a variety of PFAAs for activity associated with activation of peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ). Here we use primary hepatocytes to further assess the biological activity of a similar group of PFAAs using custom designed Taqman Low Density Arrays. Primary mouse and human hepatocytes were cultured for 48 h in the presence of varying concentrations of 12 different PFAAs or Wy14,643, a known activator of PPAR $\alpha$ . Total RNA was collected and the expression of 48 mouse or human genes evaluated. Gene selection was based on either in-house liver microarray data (mouse) or published data using primary hepatocytes (human). Gene expression in primary mouse hepatocytes was more restricted than expected. Genes typically regulated in whole tissue by PPAR $\alpha$  agonists were not altered in mouse cells including *Acox1*, *Me1*, *Acaa1a*, *Hmgcs1*, and *Slc27a1*. *Cyp2b10*, a gene regulated by the constitutive androstane receptor and a transcript normally up-regulated by in vivo exposure to PFAAs, was also unchanged in cultured mouse hepatocytes. *Cyp4a14*, *Ehhadh*, *Pdk4*, *Cpt1b*, and *Fabp1* were regulated as expected in mouse cells. A larger group of genes were differentially expressed in human primary hepatocytes, however, little consistency was observed across compounds with respect to which genes produced a significant dose response making the determination of relative biological activity difficult. This likely reflects weaker activation of PPAR $\alpha$  in human versus rodent cells as well as variation among individual cell donors. Unlike mouse cells, CYP2B6 was up-regulated in human hepatocytes by a number of PFAAs as was PPAR $\delta$ . Rankings were conducted on the limited dataset. In mouse hepatocytes, the pattern was similar to that previously observed in the COS-1 reporter cell assay. With the exception of PFHxA, longer chain PFAA carboxylates were the most active. The pattern was similar in human hepatocytes, although PFDA and PFOS showed higher activity than previously observed while PFOA showed somewhat less activity. These data reflect inherent challenges in using primary hepatocytes to predict toxicological response.

Published by Elsevier Ireland Ltd.

### 1. Introduction

Perfluoroalkyl acids (PFAAs) are stable man-made chemicals that have been widely used to manufacture industrial and consumer products since the 1950's. Health concerns were initially raised more than a decade ago following reports of widespread environmental distribution of perfluorooctane sulfonate (PFOS) (Giesy and Kannan, 2001). Numerous studies have since been published regarding the environmental accumulation and toxicity of perfluorinated chemicals (reviewed by Lau et al., 2007; Lindstrom et al., 2011; Stahl et al., 2011). Of particular concern are the growing number of epidemiological studies which suggest that perfluorooctanoic acid (PFOA) and certain other PFAAs may

<sup>☆</sup> The information in this document has been funded by the U.S. Environmental Protection Agency. It has been subjected to review by the National Health and Environmental Effects Research Laboratory and approved for publication. Approval does not signify that the contents reflect the views of the Agency, nor does mention of trade names or commercial products constitute endorsement or recommendation for use.

\* Corresponding author at: U.S. Environmental Protection Agency, MD 72, Research Triangle Park, NC 27711, USA. Tel.: +1 919 541 2223; fax: +1 919 541 4017.

E-mail address: [rosen.mitch@epa.gov](mailto:rosen.mitch@epa.gov) (M.B. Rosen).

influence human health (reviewed by Olsen et al., 2009; Post et al., 2012; Stahl et al., 2011; Steenland et al., 2010). The associative effects reported in these studies, however, tend to be modest and causality remains unclear due to inconsistencies across studies as well as their reliance on cross-sectional designs (Kerger et al., 2011; Olsen et al., 2009; Savitz, 2007; Steenland et al., 2010). While most studies have focused on either PFOA or PFOS, National Health and Nutrition Examination Survey (NHANES) data indicates that at least four PFAAs are routinely found in human sera; PFOA, PFOS, perfluorononanoic acid (PFNA), and perfluorohexane sulfonate (PFHxS) (Kato et al., 2011).

In general, PFAAs are members of a diverse group of compounds known to activate peroxisome proliferator-activated receptor- $\alpha$  (PPAR $\alpha$ ), although their biological activity extends beyond activation of this single nuclear receptor (Cheng and Klaassen, 2008; Ren et al., 2009; Rosen et al., 2008b; White et al., 2011). Compared to PFOA and PFOS, however, less is known about the relative biological activity of other PFAAs. To address this question, our group has previously utilized a transiently transfected COS-1 luciferase reporter cell assay to examine the activity of

various PFAAs with respect to PPAR $\alpha$  activation. PFAAs with either carboxylic acid or sulfonic acid side groups and of varying carbon chain length from C4 through C12 were considered in both mouse and human reporter constructs. It was found that murine PPAR $\alpha$  was more responsive than human PPAR $\alpha$  across the various PFAAs. There was also a tendency for longer carbon chain PFAAs up to C9 to be more robust activators of PPAR $\alpha$  than shorter chain PFAAs as well as a tendency for carboxylate PFAAs to be more potent than sulfonate PFAAs (Wolf et al., 2008, 2012).

Here we use primary mouse and human hepatocytes and custom made Taqman arrays to evaluate the same group of PFAAs as previously studied in COS-1 cells. Genes evaluated included those regulated by PPAR $\alpha$  as well as transcripts regulated independently of this nuclear receptor. The goal of the study was to provide additional data regarding the relative biological activity of an assorted group of PFAAs. The primary cell model should more closely resemble whole tissue *in vivo* and offer a direct and timely comparison between rodent and human for species extrapolation in the health risk assessment of this class of chemicals.

**Table 1**  
Genes included on custom mouse TLDA card.

| Gene symbol            | EntrezGene # | Gene name   | Taqman assay  |
|------------------------|--------------|---|---------------|
| A2m <sup>a</sup>       | 232345       | Alpha-2-macroglobulin   | Mm00558642.m1 |
| Acaa1a <sup>a</sup>    | 113868       | Acetyl-Coenzyme A acyltransferase 1A  | Mm00728460.s1 |
| Acox1 <sup>a</sup>     | 11430        | Acyl-Coenzyme A oxidase 1, palmitoyl  | Mm00443579.m1 |
| Actb                   | 11461        | Actin, beta, cytoplasmic  | Mm00607939.s1 |
| Atf3                   | 11910        | Activating transcription factor 3   | Mm00476032.m1 |
| B2m                    | 12010        | Beta-2 microglobulin  | Mm00437762.m1 |
| Baat4 <sup>a</sup>     | 12012        | Bile acid-Coenzyme A: amino acid N-acyltransferase                          | Mm00476075.m1 |
| C9 <sup>a</sup>        | 12279        | Complement component 9  | Mm00442739.m1 |
| Ccnd1                  | 12443        | Cyclin D1   | Mm00432359.m1 |
| Cpt1b <sup>a</sup>     | 12895        | Carnitine palmitoyltransferase 1b   | Mm00487200.m1 |
| Cyp1a1                 | 13076        | Cytochrome P450, family 1, subfamily a, polypeptide 1                       | Mm00487218.m1 |
| Cyp2b10 <sup>a</sup>   | 13088        | Cytochrome P450, family 2, subfamily b, polypeptide 10                      | Mm00456591.m1 |
| Cyp3a11                | 13112        | Cytochrome P450, family 3, subfamily a, polypeptide 11                      | Mm00731567.m1 |
| Cyp4a14 <sup>a</sup>   | 13119        | Cytochrome P450, family 4, subfamily a, polypeptide 14                      | Mm00484132.m1 |
| Cyp7a1 <sup>a</sup>    | 13122        | Cytochrome P450, family 7, subfamily a, polypeptide 1                       | Mm00484152.m1 |
| Ehhadh <sup>a</sup>    | 74147        | Enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase          | Mm00470091.s1 |
| Fabp1 <sup>a</sup>     | 2168         | Fatty acid binding protein 1, liver   | Mm00444340.m1 |
| Gadd45b <sup>a</sup>   | 17873        | Growth arrest and DNA-damage-inducible 45 beta                              | Mm00435123.m1 |
| Gapdh                  | 14433        | Glyceraldehyde-3-phosphate dehydrogenase                                    | Mm99999915.g1 |
| Gclc                   | 14629        | Glutamate-cysteine ligase, catalytic subunit                                | Mm00802655.m1 |
| Hadha <sup>a</sup>     | 97212        | Hydroxyacyl-Coenzyme A dehydrogenase (trifunctional protein), alpha subunit | Mm00805228.m1 |
| Hmgcs1 <sup>a</sup>    | 208715       | 3-Hydroxy-3-methylglutaryl-Coenzyme A synthase 1                            | Mm00524111.m1 |
| Lss                    | 16987        | Lanosterol synthase   | Mm00461312.m1 |
| Mbl2 <sup>a</sup>      | 17195        | Mannose binding lectin (C)  | Mm00487623.m1 |
| Me1 <sup>a</sup>       | 17436        | Malic enzyme 1, NADP(+)-dependent, cytosolic                                | Mm00782380.s1 |
| Nfe2l2                 | 18024        | Nuclear factor, erythroid derived 2, like 2                                 | Mm00477784.m1 |
| Pdk4 <sup>a</sup>      | 27273        | Pyruvate dehydrogenase kinase, isoenzyme 4                                  | Mm00443325.m1 |
| Peci <sup>a</sup>      | 23986        | Peroxisomal delta3, delta2-enoil-Coenzyme A isomerase                       | Mm00478725.m1 |
| Pex11a <sup>a</sup>    | 18631        | Peroxisomal biogenesis factor 11a   | Mm00478137.m1 |
| Por <sup>a</sup>       | 18984        | P450 (cytochrome) oxidoreductase  | Mm00435876.m1 |
| Ppara                  | 19013        | Peroxisome proliferator activated receptor alpha                            | Mm00440939.m1 |
| Ppard                  | 19015        | Peroxisome proliferator activator receptor delta                            | Mm01305433.m1 |
| Pparg                  | 19016        | Peroxisome proliferator activated receptor gamma                            | Mm00440945.m1 |
| Ppargc1a               | 19017        | Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha     | Mm00447183.m1 |
| Pxmp4 <sup>a</sup>     | 59038        | Peroxisomal membrane protein 4  | Mm00480657.m1 |
| Serpina1a <sup>a</sup> | 20700        | Serine (or cysteine) peptidase inhibitor, clade A, member 1a                | Mm02748447.g1 |
| Nos2 (iNos)            | 18126        | Nitric oxide synthase 2, inducible  | Mm00440502.m1 |
| Hmox1                  | 15368        | Heme oxygenase (decycling)  | Mm00516005.m1 |
| Ddit3                  | 13198        | DNA-damage inducible transcript 3   | Mm00492097.m1 |
| Scd1 <sup>a</sup>      | 20249        | Stearoyl-Coenzyme A desaturase 1  | Mm00772290.m1 |
| Gstm4 <sup>a</sup>     | 14865        | Glutathione S-transferase, mu 4   | Mm00728197.s1 |
| Ces1 <sup>a</sup>      | 12623        | Carboxylesterase 1  | Mm00491334.m1 |
| Abcc4 (Mrp4)           | 239273       | ATP-binding cassette, sub-family C (CFTR/MRP), member 4                     | Mm01226380.m1 |
| Abcb1b (Mdr1b)         | 18669        | ATP-binding cassette, sub-family B (MDR/TAP), member 1B                     | Mm00440736.m1 |
| CD36 <sup>a</sup>      | 12491        | CD36 antigen  | Mm01135198.m1 |
| Slc27a1 <sup>a</sup>   | 26457        | Solute carrier family 27 (fatty acid transporter), member 1                 | Mm00449511.m1 |
| Slco1a1 (Oatp1)        | 28248        | Solute carrier organic anion transporter family, member 1a1                 | Mm00649796.m1 |
| Mogat1 <sup>a</sup>    | 68393        | Monoacylglycerol O-acyltransferase 1  | Mm00503358.m1 |

<sup>a</sup> Regulation previously observed in whole tissue following PFAA exposure.

Download English Version:

<https://daneshyari.com/en/article/5859441>

Download Persian Version:

<https://daneshyari.com/article/5859441>

[Daneshyari.com](https://daneshyari.com)